Sort   by:  
 Page size 
UnknownIdentification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study.

Background

The clinical presentation of COVID-19 in patients admitted to hospital is heterogeneous. We aimed to determine whether clinical phenotypes of patients with COVID-19 can be derived from clinical data, to assess the reproducibility of these phenotypes and correlation with prognosis,...
S-EPMC7906623 | biostudies-literature
UnknownOne-year mortality after ICU admission due to COVID-19 infection.
Not available
S-EPMC8764887 | biostudies-literature
UnknownKey Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients.

Introduction

Critical COVID-19 survivors have a high risk of respiratory sequelae. Therefore, we aimed to identify key factors associated with altered lung function and CT scan abnormalities at a follow-up visit in a cohort of critical COVID-19 survivors.

Methods

Multicenter ambispect...
S-EPMC9824938 | biostudies-literature
UnknownMajor candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study.

Purpose

Although there is evidence supporting the benefits of corticosteroids in patients affected with severe coronavirus disease 2019 (COVID-19), there is little information related to their potential benefits or harm in some subgroups of patients admitted to the intensive care unit (ICU) ...
S-EPMC9211796 | biostudies-literature
UnknownProcalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients.

Purpose

Although the prevalence of community-acquired respiratory bacterial coinfection upon hospital admission in patients with coronavirus disease 2019 (COVID-19) has been reported to be < 5%, almost three-quarters of patients received antibiotics. We aim to investigate whether procalciton...
S-EPMC10425511 | biostudies-literature
UnknownEffects of intubation timing in patients with COVID-19 throughout the four waves of the pandemic: a matched analysis.

Background

The primary aim of our study was to investigate the association between intubation timing and hospital mortality in critically ill patients with coronavirus disease 2019 (COVID-19)-associated respiratory failure. We also analysed both the impact of such timing throughout the first...
S-EPMC9686319 | biostudies-literature
UnknownClustering COVID-19 ARDS patients through the first days of ICU admission. An analysis of the CIBERESUCICOVID Cohort.

Background

Acute respiratory distress syndrome (ARDS) can be classified into sub-phenotypes according to different inflammatory/clinical status. Prognostic enrichment was achieved by grouping patients into hypoinflammatory or hyperinflammatory sub-phenotypes, even though the time of analysis...
S-EPMC10958830 | biostudies-literature
UnknownImmunosuppressed patients with COVID-19 pneumonia in ICU: clinical characteristics and factors influencing outcomes.

Introduction

COVID-19 severely impacted global health, especially older adults and those with comorbidities. Immunosuppressed patients are at high risk for severe outcomes, yet studies yield conflicting mortality rates for this group. This study examines the clinical characteristics and outc...
S-EPMC12645730 | biostudies-literature
UnknownThe evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients.

Background

Mortality due to COVID-19 is high, especially in patients requiring mechanical ventilation. The purpose of the study is to investigate associations between mortality and variables measured during the first three days of mechanical ventilation in patients with COVID-19 intubated at...
S-EPMC8436582 | biostudies-literature
UnknownEfficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial.

Background

There are no specific generally accepted therapies for the coronavirus disease 2019 (COVID-19). The full spectrum of COVID-19 ranges from asymptomatic disease to mild respiratory tract illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multisystem organ failu...
S-EPMC7429135 | biostudies-literature
Sort   by:  
 Page size